Paul Tudor Jones’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.34M | Buy |
25,000
+19,839
| +384% | +$5.63M | 0.01% | 1026 |
|
|
2026
Q1 | $1.44M | Buy |
+5,161
| New | +$1.49M | ﹤0.01% | 2102 |
|
|
2025
Q1 | – | Sell |
-7,433
| Closed | -$2.44M | – | 3062 |
|
|
2024
Q4 | $2.44M | Buy |
+7,433
| New | +$2.52M | 0.01% | 1119 |
|
|
2024
Q1 | – | Sell |
-16,070
| Closed | -$5.19M | – | 2233 |
|
|
2023
Q4 | $5.19M | Buy |
16,070
+9,015
| +128% | +$2.83M | 0.04% | 615 |
|
|
2023
Q3 | $2.53M | Buy |
+7,055
| New | +$2.72M | 0.03% | 807 |
|
|
2023
Q2 | – | Sell |
-13,759
| Closed | -$6.59M | – | 2444 |
|
|
2023
Q1 | $6.59M | Sell |
13,759
-1,554
| -10% | -$727K | 0.1% | 264 |
|
|
2022
Q4 | $6.44M | Buy |
15,313
+2,730
| +22% | +$1.1M | 0.13% | 180 |
|
|
2022
Q3 | $5.25M | Buy |
12,583
+11,645
| +1,241% | +$5.81M | 0.11% | 210 |
|
|
2022
Q2 | $464K | Sell |
938
-5,298
| -85% | -$2.76M | 0.01% | 1311 |
|
|
2022
Q1 | $3.51M | Sell |
6,236
-113
| -2% | -$68.1K | 0.08% | 310 |
|
|
2021
Q4 | $4.8M | Buy |
6,349
+5,812
| +1,082% | +$4.35M | 0.08% | 275 |
|
|
2021
Q3 | $401K | Sell |
537
-6,291
| -92% | -$4.71M | 0.01% | 1807 |
|
|
2021
Q2 | $4.4M | Buy |
6,828
+351
| +5% | +$214K | 0.08% | 268 |
|
|
2021
Q1 | $3.7M | Buy |
6,477
+6,071
| +1,495% | +$3.6M | 0.07% | 277 |
|
|
2020
Q4 | $237K | Sell |
406
-5,033
| -93% | -$2.87M | 0.01% | 1185 |
|
|
2020
Q3 | $2.8M | Buy |
5,439
+2,586
| +91% | +$1.31M | 0.12% | 191 |
|
|
2020
Q2 | $1.29M | Buy |
+2,853
| New | +$1.26M | 0.06% | 398 |
|
|
2018
Q4 | – | Sell |
-1,917
| Closed | -$600K | – | 1011 |
|
|
2018
Q3 | $600K | Buy |
+1,917
| New | +$595K | 0.02% | 627 |
|
|
2018
Q1 | – | Sell |
-2,580
| Closed | -$616K | – | 1004 |
|
|
2017
Q4 | $616K | Buy |
+2,580
| New | +$625K | 0.02% | 518 |
|
|
2017
Q3 | – | Sell |
-9,000
| Closed | -$2.04M | – | 1094 |
|
|
2017
Q2 | $2.04M | Sell |
9,000
-1,722
| -16% | -$375K | 0.06% | 189 |
|
|
2017
Q1 | $2.14M | Sell |
10,722
-48,378
| -82% | -$9.32M | 0.07% | 185 |
|
|
2016
Q4 | $10.8M | Buy |
59,100
+54,616
| +1,218% | +$9.31M | 0.28% | 59 |
|
|
2016
Q3 | $735K | Buy |
+4,484
| New | +$681K | 0.02% | 543 |
|
|
2016
Q2 | – | Sell |
-3,335
| Closed | -$456K | – | 1634 |
|
|
2016
Q1 | $456K | Sell |
3,335
-265
| -7% | -$34.8K | 0.01% | 1009 |
|
|
2015
Q4 | $499K | Buy |
3,600
+156
| +5% | +$21.6K | 0.01% | 879 |
|
|
2015
Q3 | $463K | Sell |
3,444
-2,487
| -42% | -$358K | 0.02% | 816 |
|
|
2015
Q2 | $893K | Sell |
5,931
-1,712
| -22% | -$245K | 0.03% | 474 |
|
|
2015
Q1 | $1.03M | Sell |
7,643
-50,917
| -87% | -$6.31M | 0.03% | 366 |
|
|
2014
Q4 | $7.06M | Buy |
58,560
+50,546
| +631% | +$5.82M | 0.25% | 52 |
|
|
2014
Q3 | $909K | Buy |
8,014
+2,064
| +35% | +$245K | 0.03% | 335 |
|
|
2014
Q2 | $712K | Buy |
5,950
+300
| +5% | +$36.6K | 0.03% | 352 |
|
|
2014
Q1 | $724K | Sell |
5,650
-1,795
| -24% | -$230K | 0.03% | 335 |
|
|
2013
Q4 | $920K | Buy |
7,445
+2,845
| +62% | +$347K | 0.04% | 225 |
|
|
2013
Q3 | $541K | Buy |
4,600
+100
| +2% | +$11.8K | 0.02% | 309 |
|
|
2013
Q2 | $505K | Buy |
+4,500
| New | +$528K | 0.04% | 325 |
|
Other funds holding BIO
AI
Paul Tudor Jones's BIO Position: Q2 2026 in Review
Paul Tudor Jones increased its Bio-Rad Laboratories Class A (BIO) stake by 384% in Q2 2026, buying an estimated $5.63M and bringing the position to 25,000 shares worth $7.34M. The position accounts for 0.01% of the portfolio, ranked #1026.
Paul Tudor Jones first reported a position in BIO in Q2 2013 and has held it in 35 quarters since. The position peaked at $10.8M in Q4 2016. 396 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Paul Tudor Jones held 25,000 shares of Bio-Rad Laboratories Class A worth $7.34M as of Q2 2026.
- Paul Tudor Jones bought 19,839 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $5.63M.
- Bio-Rad Laboratories Class A made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1026 holding.
- Paul Tudor Jones first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 35 quarters since.
- Paul Tudor Jones's Bio-Rad Laboratories Class A position peaked at $10.8M in Q4 2016.
- 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.